Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716195 · ClinicalTrials.gov registry record · Phase 2
Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01716195 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 18 participants.
The verdict
NCT01716195, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).
Interventions
- RADIATION Induction Chemotherapy followed by Response Adapted Chemoradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-10 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716195
The ClinicalTrials.gov registry entry for NCT01716195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Induction Chemotherapy followed by Response Adapted Chemoradiation is the first listed.
NCT01716195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716195 about?
NCT01716195 is a clinical study titled "Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer". The purpose of this study is to determine whether human papillomavirus (HPV)-positive head and neck cancer can be treated with a less aggressive regimen of radiation therapy and chemotherapy (paclitaxel) after initially receiving two cycles of chemotherapy (carboplatin/paclitaxel).
What is the current status of trial NCT01716195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2012-10. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT01716195?
The interventions under investigation include: Induction Chemotherapy followed by Response Adapted Chemoradiation (RADIATION).
Who is sponsoring clinical trial NCT01716195?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.